William Blair also issued estimates for Nayax’s FY2025 earnings ... cloud-based management platform; Retail Management Cloud, a comprehensive attended retail management platform; Loyalty and ...

William Blair initiated coverage of Xencor (XNCR) with an Outperform rating. The firm believes the biopharmaceutical industry is entering a ...

William Blair also issued estimates for J.Jill’s Q3 2026 earnings ... The company markets its products through retail stores, website, and catalogs. J.Jill, Inc was founded in 1959 and is ...

William Blair initiated coverage of Kalaris Therapeutics (KLRS) with an Outperform rating and $21 fair value estimate. Kalaris is a clinical-stage biotechnology company developing therapies for ...

In this article, we are going to take a look at where William Blair Small-Mid Cap Growth R6 ... on bonds and U.S. stock funds ...

Analysts at William Blair highlighted the company’s valuation, trading at 19 times EBITDA and 38 times P/FCF, or 32 times excluding certain capital expenditures, based on their 2025 estimates.

As a result, William Blair lowered its delivery estimates for the first quarter from 418,000 to 350,000 and for the full year from 1.94 million to 1.68 million. Despite these concerns, the firm ...

Analysts at William Blair highlighted the company’s valuation, trading at 19 times EBITDA and 38 times P/FCF, or 32 times excluding certain capital expenditures, based on their 2025 estimates.

As a result, William Blair lowered its delivery estimates for the first quarter from 418,000 to 350,000 and for the full year from 1.94 million to 1.68 million. Despite these concerns, the firm ...